Prometheus Laboratories Announces the Launch of PredictrPKTM IFX, A Revolutionary Test Enabling Precision-Guided Dosing for Inflammatory Bowel Diseasenischal kashyap2022-02-23T09:34:15-08:00
Prometheus Laboratories Announces New Agreement with MultiPlan, Expanding Patient Access to Specialized GI Testingprometheuslabs2021-11-15T02:14:33-08:00
Prometheus Laboratories Announces Multiple Presentations on Precision-Guided Dosing and Monitoring at the Digestive Disease Week 2021 Annual Meetingprometheuslabs2021-11-15T02:09:44-08:00